$1,318.00
This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, prevalence data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, and prevalence data, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Symptoms
7 Patient subtypes
8 Risk factors
8 Diagnosis
10 TREATMENT
10 Pharmacological therapies
11 Anticonvulsants
11 Other treatments
12 EPIDEMIOLOGY
13 MARKETED DRUGS
15 PIPELINE DRUGS
20 RECENT EVENTS AND ANALYST OPINION
20 NYX-2925 for Fibromyalgia (August 12, 2022)
21 Tonmya for Fibromyalgia (March 21, 2022)
23 KEY UPCOMING EVENTS
24 PROBABILITY OF SUCCESS
25 REVENUE OPPORTUNITY
26 CLINICAL TRIAL LANDSCAPE
27 Sponsors by status
28 Sponsors by phase
29 Recent events
31 BIBLIOGRAPHY
32 APPENDIX
LIST OF FIGURES
15 Figure 1: Overview of pipeline drugs for fibromyalgia in the US
15 Figure 2: Pipeline drugs for fibromyalgia, by company
16 Figure 3: Pipeline drugs for fibromyalgia, by drug type
16 Figure 4: Pipeline drugs for fibromyalgia, by classification
23 Figure 5: Key upcoming events in fibromyalgia
24 Figure 6: Probability of success in the pain pipeline
26 Figure 7: Clinical trials in fibromyalgia
26 Figure 8: Top 10 drugs for clinical trials in fibromyalgia
27 Figure 9: Top 10 companies for clinical trials in fibromyalgia
27 Figure 10: Trial locations in fibromyalgia
28 Figure 11: Fibromyalgia trials status
29 Figure 12: Fibromyalgia trials sponsors, by phase
LIST OF TABLES
14 Table 1: Marketed drugs for fibromyalgia
17 Table 2: Pipeline drugs for fibromyalgia in the US
20 Table 3: NYX-2925 for Fibromyalgia (August 12, 2022)
21 Table 4: Tonmya for Fibromyalgia (March 21, 2022)
25 Table 5: Historical global sales, by drug ($m), 2017–21
25 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!